指南与共识心脑血管急症儿科与产科急症重症综合管理与镇静镇痛

儿童嗜铬细胞瘤围术期血压管理推荐:十年叙述性综述

Perioperative Blood Pressure Management Recommendations in Pediatric Pheochromocytoma: A 10-Year Narrative Review.
指南 / 共识 · Kidney Blood Press Res · 2024-12-03
一句话结论儿童嗜铬细胞瘤围术期应以α受体阻滞剂快速启动降压、术中和术后维持血流动力学稳定,并常规行基因检测。

本文为叙述性综述,汇总儿童嗜铬细胞瘤围术期血压管理证据:嗜铬细胞瘤占儿童高血压1.7%,持续高血压率高达90%且与术中并发症高风险相关。推荐疑似病例立即使用α受体阻滞剂,随后可加用β受体阻滞剂对抗反射性心动过速;术前须盐和水补充充足;术中确保麻醉与手术期间血流动力学稳定并备短效静脉药物和复苏液体;术后入儿科重症监护病房密切监测至少24–48小时;所有患者推荐基因检测。未来需前瞻性多中心研究及可行时的随机对照试验,聚焦术前非选择性对比选择性α受体阻滞剂的疗效与安全性。

要点

  • 疑似儿童嗜铬细胞瘤应即刻使用降压药,主要为α受体阻滞剂;β受体阻滞剂可随后引入以对抗反射性心动过速。
  • 术前必须达到盐和水补充充足,以降低术中血流动力学不稳定风险。
  • 术中应确保麻醉和手术期间血流动力学稳定,并备好短效静脉药物和复苏液体。
  • 术后应收入儿科重症监护病房密切监测至少24–48小时。
  • 推荐所有嗜铬细胞瘤患者行基因检测,识别如琥珀酸脱氢酶B亚基等突变以指导治疗和预后。

适用人群与场景

  • 儿童嗜铬细胞瘤患者(嗜铬细胞瘤占儿童高血压病例的1.7%),持续高血压率高达90%,与术中并发症高风险相关。
  • 适用场景为围术期(术前、术中、术后)血压管理。

处置流程与药物剂量

  • 疑似嗜铬细胞瘤应即刻给予降压药,主要为α受体阻滞剂。
  • β受体阻滞剂可在α受体阻滞剂之后引入,以对抗反射性心动过速。
  • 术前必须使患者盐和水补充充足。
  • 术中应确保麻醉和手术期间血流动力学稳定,并备好短效静脉药物和复苏液体。
  • 术后收入儿科重症监护病房密切监测至少24–48小时。
  • 推荐所有嗜铬细胞瘤患者行基因检测。

研究设计与关键结果

  • 叙述性综述:儿童嗜铬细胞瘤围术期血压管理文献有限,持续高血压率高达90%且与术中并发症高风险相关。
  • 20世纪后半叶由于有效的围术期血压管理,死亡率显著下降。
  • 手术切除是嗜铬细胞瘤的确定性治疗,但伴随血流动力学不稳定和心血管并发症风险。

证据类型、等级与局限

  • 证据类型:叙述性综述(十年叙述性综述)。
  • 局限:儿童嗜铬细胞瘤血压管理文献有限;未来研究应优先设计良好的前瞻性多中心研究并具备足够样本量,在可行时开展标准化方案和适当终点的随机对照试验。

对床旁实践的改变

  • 对疑似儿童嗜铬细胞瘤,作者建议立即使用α受体阻滞剂降压,随后可加用β受体阻滞剂对抗反射性心动过速。
  • 作者强调术前盐和水补充充足、术中血流动力学稳定、术后儿科重症监护病房监测至少24–48小时。
  • 作者推荐所有嗜铬细胞瘤患者行基因检测以识别如琥珀酸脱氢酶B亚基等突变,指导治疗策略和预后。
  • 作者认为未来研究应聚焦术前非选择性对比选择性α受体阻滞剂(单药或联合钙通道阻滞剂和/或β受体阻滞剂)或不使用术前降压药的疗效与安全性。

指南或共识出处

  • Perioperative Blood Pressure Management Recommendations in Pediatric Pheochromocytoma: A 10-Year Narrative Review(Kidney Blood Press Res)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pheochromocytomas and paragangliomas are rare chromaffin cell-derived tumors characterized by catecholamine-secreting activity. Pheochromocytomas account for 1.7% of pediatric hypertension cases. Surgical resection, the definitive pheochromocytoma treatment, carries risks of hemodynamic instability and cardiovascular complications. Nevertheless, mortality rates decreased significantly in the latter half of the 20th century due to effective perioperative blood pressure (BP) management. The literature on BP management tailored to pediatric pheochromocytoma is limited, while the sustained hypertension rate in this population is high (up to 90%) and related to a high risk of intraoperative complications. In this narrative review, we provide up-to-date recommendations regarding BP management to minimize perioperative comorbidities in children with pheochromocytoma.

SUMMARY: Antihypertensive agents, primarily alpha (α)-blockers, should be promptly administered for suspected pheochromocytoma. Beta (β)-blockers may be introduced thereafter to counteract reflex tachycardia. The patient must be salt- and water-replete preoperation. Intraoperatively, stable hemodynamics should be ensured during anesthesia and surgery, and short-acting intravenous medications and resuscitation fluid should be supplied. Postoperatively, patients should be admitted to the pediatric intensive care unit for close monitoring for at least 24-48 h. Genetic testing is recommended for all pheochromocytoma patients. Identifying underlying mutations, like in succinate dehydrogenase subunit B, which is linked to a higher risk of multifocality and metastasis, is imperative for tailoring treatment strategies and prognostication.

KEY MESSAGES: Achieving optimal outcomes in pediatric pheochromocytoma relies on preoperative BP optimization with appropriate antihypertensive agents, intraoperative hemodynamic stability, and postoperative routine long-term follow-up to monitor for complications, recurrence, and metastasis. Future research should prioritize well-designed prospective multicenter studies with adequate sample sizes and, where feasible, randomized controlled trials with standardized protocols and appropriate endpoints. These studies should focus on the efficacy and safety of preoperative nonselective versus selective α-blockers, whether as monotherapy or combined with other medications (e.g., calcium channel blockers and/or β-blockers), or treatment without preoperative anti-hypertensives.

来源:Kidney Blood Press Res,查看原文。版权归原作者所有。

参考来源

  1. Ambarsari CG, Nadhifah N, Lestari HI, et al. Perioperative Blood Pressure Management Recommendations in Pediatric Pheochromocytoma: A 10-Year Narrative Review. Kidney Blood Press Res. 2024. PMID: 39626645. doi:10.1159/000542897

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。